Quinoline sulfonamides and their therapeutic use

A compound of the general formula (i) ##STR5## wherein R is selected from the group consisting of H, halogen, and alkyl;

• R.sub.1 is selected from the group consisting of OH, alkoxy optionally substituted with one or more halogens, and thioalkyl;
• R.sub.2, R.sub.3, and R.sub.4 are the same or different and are each selected from the group consisting of H, R.sub.7, OR.sub.11, COR.sub.7, C(.dbd.NOR.sub.7)R.sub.7, alkyl-C(.dbd.NOR.sub.7)R.sub.7 alkyl-C(.dbd.NOR)R.sub.7, C(.dbd.NOH)R.sub.7, halogen, CF.sub.3, CN, CO.sub.2 H, CO.sub.2 R.sub.11, CONH.sub.2, CONHR.sub.7, CON(R.sub.7).sub.2, NR.sub.9 R.sub.10, and CONR.sub.12 R.sub.13 where NR.sub.12 R.sub.13 is a heterocyclic ring optionally substituted with one or more R.sub.15 ;
• R.sub.5 is selected from the group consisting of arylalkyl, heteroarylalkyl, S(O).sub.m R.sub.11, and alkyl optionally substituted with one or more substituents selected from the group consisting of hydroxy, alkoxy, CO.sub.2 R.sub.8, SO.sub.2 NR.sub.12 R.sub.13, CONR.sub.12 R.sub.13, CN, NR.sub.9 R.sub.10, COR.sub.11, and S(O).sub.n R.sub.11 ;
• for R.sub.5 and/or R.sub.6, the aryl/heteroaryl portion is optionally substituted with one or more substituents alkyl-R.sub.14 or R.sub.14 ;
• R.sub.6 is selected from the group consisting of aryl, heteroaryl, arylalkyl, and heteroarylalkyl;
• R.sub.7 represents R.sub.11 optionally substituted at any position with one or more R.sub.16 ;
• R.sub.8 is selected from the group consisting of H, alkyl, cycloalkyl, arylalkyl, heteroarylalkyl, and heterocycloalkyl;
• R.sub.9 is selected from the group consisting H, aryl, heteoaryl, heterocyclo, alkyl, cycloalkyl, arylalkyl, heteroarylalkyl, heterocyclalkyl, alkylcarbonyl, alkoxycarbonyl, arylsulphonyl, heteroarylsulphonyl, heterocyclosulphonyl, arylcarbonyl, heteroarylcarbonyl, heterocyclocarbonyl, and alkylsulphonyl;
• R.sub.10 is selected from the group consisting of H, aryl, heteroaryl, heterocyclo, alkyl, cycloalkyl, arylalkyl, heteroarylalkyl, and heterocycloalkyl;
• R.sub.11 is selected from the group consisting of alkyl, cycloalkyl, aryl, heteroaryl, heterocyclo, arylalkyl, heteroarylalkyl, and heterocycloalkyl;
• R.sub.12 and R.sub.13 are the same or different and are each selected from the group consisting of H and R.sub.11, or NR.sub.12 R.sub.13 represents a heterocyclic ring as defined above;
• Rhd 14 is selected from the group consisting of alkyl (optionally substituted by one or more halogens), cycloalkyl, aryl, heteroaryl, heterocyclo, hydroxy, alkoxy (optionally substituted by one or more halogens), thioalkyl, aryloxy, heteroaryloxy, heterocyclooxy, arylalkyloxy, heteroarylalkyloxy, heterocycloalkyloxy, CO.sub.2 R.sub.4, CONR.sub.12 R.sub.13, SO.sub.2 NR.sub.12 R.sub.13, halogen, --CN, --NR.sub.9 R.sub.10, COR.sub.11, S(O).sub.n R.sub.11, and carbonyl oxygen;
• R.sub.15 is selected from the group consisting of alkyl, arylalkyl, and heteroarylalkyl;
• R.sub.16 is selected from the group consisting of alkyl, OH, OR.sub.11, NR.sub.9 R.sub.10, CN, CO.sub.2 H, CO.sub.2 R.sub.11, CONR.sub.12 R.sub.13, and COR.sub.11 ;
• m is an integer of up to 2;
• and
• n=0-2;
• or a pharmaceutically acceptable salt thereof.